Citations |
EMBO Mol Med. 2022 Dec 13;e16373.<br/>Front Immunol. 2021 Feb 2;11:625542.<br/>Harvard Medical School LINCS LIBRARY<br/>Aging Cell. 2020 Oct;19(10):e13217.<br/>Aging Cell. 2022 Feb 23;e13573.<br/>Biomolecules. 2022, 12(3), 426.<br/>FASEB J. 2019 Feb;33(2):2435-2450. <br/>J Clin Invest. 2021 Dec 29;e150101.<br/>Mol Med Rep. 2017 Nov;16(5):5924-5930.<br/>Nat Commun. 2018 Sep 11;9(1):3688.<br/>Neurogastroenterol Motil. 2020 Oct;32(10):1514-1528.<br/>[1]Wilkinson SE, et al. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J. 1993 Sep 1;294 (Pt 2):335-7.<br/>[2]Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.<br/>[3]Tian F, et al. Inhibition of protein kinase C protects against paraoxon-mediated neuronal cell death. Neurotoxicology. 2007 Jul;28(4):843-9. Epub 2007 Apr 20.<br/>[4]Hambleton M, et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation. 2006 Aug 8;114(6):574-82. |
Product Description |
Ro 31-8220 mesylate is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. |